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Abstract
The objective of this study was to determine the efﬁcacy and safety of frequently inhaled nebulized hypertonic saline (HS) in infants with
moderate to severe bronchiolitis. One hundred and twenty-six infants were randomized to receive either nebulized 3% hypertonic saline
(HS) or 0.9% normal saline (NS), but only 112 patients completed the whole study. Cough, wheezing, pulmonary physical signs, clinical
severity scores and the hospital length of stay (LOS) were recorded. The wheezing remission time was 4.8 ± 1.0 days in the NS group and
3.6 ± 0.9 days in the HS group (p <0.01). The cough remission time was 5.5 ± 0.9 days in the NS group and 4.3 ± 0.7 days in the HS group
(p <0.01). The moist crackles disappeared at 6.2 ± 0.7 days in the NS group and at 4.4 ± 0.9 days in the HS group (p <0.01). The clinical
severity scores decreased more signiﬁcantly in the HS group than in the NS group on each day within 96 h after enrolment (p <0.01). The
LOS decreased from 6.4 ± 1.4 days in the NS group to 4.8 ± 1.2 days in the HS group (p <0.01). The treatment was well tolerated, with
no adverse effects attributable to nebulized HS. The conclusions are that frequently inhaled HS relieved symptoms and signs faster than
NS, and shortened LOS signiﬁcantly for infants with moderate to severe bronchiolitis, without apparent adverse effects.
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Introduction
Bronchiolitis is infection of the bronchial and bronchiolar epi-
thelium, which is mainly caused by respiratory syncytial virus
(RSV). The primary treatment remains largely supportive, with
mechanical ventilatory support as needed [1]. Other types of
treatment remain controversial [1,2]. It has been shown that
nebulized hypertonic saline (HS) decreases the hospital length
of stay (LOS) as compared with normal saline (NS) among
infants hospitalized with viral bronchiolitis [3,4]. We and other
researchers demonstrated that nebulized HS and bronchodila-
tors decreased symptoms and LOS for infants with mild to
moderate viral bronchiolitis [5–7]. Both of the aforemen-
tioned studies used three times per day dosing, which is signiﬁ-
cantly less than the three to six times per hour regimens often
used to children in respiratory distress [8–10]. Children with
moderate to severe bronchiolitis have difﬁculty in breathing.
Frequently inhaled nebulized HS reduced the LOS for infants
with moderately severe bronchiolitis [3]. The present study
was performed to investigate frequently inhaled nebulized HS
for moderate to severe bronchiolitis in a prospective, random-
ized, double-blind, controlled fashion. The primary objective
was to compare the symptoms, signs, clinical severity scores
and the LOS of these infants with those of a control group of
infants receiving frequently inhaled nebulized NS.
Materials and Methods
Patients
Infants aged <24 months with a ﬁrst episode of wheezing
admitted to the Children’s Hospital, Chongqing Medical Uni-
versity in China for the treatment of moderate to severe
bronchiolitis were eligible for the study. The patients were
ranked as moderately to severely ill according to the clinical
score system, as follows [11]. (i) respiratory rate: 0 points,
<30 breaths/min; 1 point, 31–45 breaths/min; 2 points, 46–
60 breaths/min; 3 points, >60 breaths/min. (ii) Wheezing:
0 points, none; 1 point, terminal expiratory or heard only
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with a stethoscope; 2 points, entire expiration or audible on
expiration without a stethoscope; 3 points, inspiration and
expiration without a stethoscope. (iii) Retractions: 0 points,
none; 1 point, intercostal only; 2 points, tracheosternal;
3 points, severe with nasal ﬂaring. (iv) General condition:
0 points, normal; 3 points, irritable, lethargic, poor feeding.
Regarding the clinical total score, the disease severity can be
divided into the following ranks: 0–4.9 points, mild; 5–
8.9 points, moderate; and 9–12 points, severe disease.
Exclusion criteria
The exclusion criteria were as follows: age >24 months, pre-
vious episode of wheezing, chronic cardiac and pulmonary
disease, immunodeﬁciency, accompanying respiratory failure,
requiring mechanical ventilation, inhaling the nebulized 3%
HS solution 12 h before treatment, and prematurity, with
birth at <34 weeks of gestation.
Study design
Infants with moderate to severe bronchiolitis were assessed
within 2 h for entry into the study. If inclusion/exclusion cri-
teria were satisﬁed, then informed consent was obtained.
Patients were randomized to receive 4 mL of a solution con-
taining either HS or NS. The random code was generated by
computer. The code was concealed in a sealed, opaque enve-
lope until the child was recruited. The solution was adminis-
tered in a double-blind fashion every 2 h for three doses,
followed by every 4 h for ﬁve doses, followed by every 6 h
until discharge [3]. Each of the two groups received the
same supportive and comprehensive treatments, including
sputum aspiration, water–electrolyte balance maintenance
and oxygen therapy. All inhaled treatments were delivered
to infants from standard air-compressed nebulizers (PARI
Corporation, Starnford, Germany). Patients were examined
at the time of study entry and every 12 h after enrolment.
No detectable differences in colour, smell or other physical
properties existed between HS and NS. The identities of the
solution were not available to the investigators, nurses or
parents. The decisions to discharge babies were made by
attending physicians when the patients had experienced no
respiratory symptoms and signs during the past 12 h. The
attending physicians were also blind to the solution.
Sample and method for detecting RSV
DNA was extracted from 200 lL of airway aspirate with the
QIAamp DNA Mini kit (Qiagen, MD, USA), and samples
were eluted in 200 lL of AE buffer. Viral antigen was analy-
sed for RSV by direct ﬂuorescent assay (D3 direct ﬂuores-
cent assay Respiratory Viruses Screening & ID Kit;
Diagnostic Hybrids, Hannover, Germany).
Ethics
The study was approved by the ethics and human research
committees of the Children’s Hospital, Chongqing Medical
University. Written informed consent was obtained from at
least one parent of each infant before enrolment.
Observation and evaluation
We evaluated these patients’ symptoms (cough, wheezing,
hoarse voice, vomiting, diarrhoea, general condition), signs
(temperature, respiratory rate, heart rate, retraction, pulmo-
nary signs, heart sounds) every 12 h after enrolment. We
recorded the clinical severity scores every 12 h after enrol-
ment, the day when cough, wheezing and pulmonary moist
crackles disappeared, and the LOS.
Statistical analyses
SPSS edition 11.5 was used to analyse all the data. Chi-
square tests were used to compare categorical variables.
One-way analysis of variance (ANOVA) was used for the
continuous variables. The mean ± standard deviation (x ± s)
expresses the central trend of the data. A p-value <0.05 was
considered to be statistically signiﬁcant.
Results
Participants’ ﬂow and baseline data
One hundred and thirty-ﬁve patients with moderate to
severe bronchiolitis were recruited from November 2008 to
November 2009 at the Children’s Hospital, Chongqing Medi-
cal University, but only 112 patients completed the whole
study (Fig. 1). Among the 112 patients, 57 were enrolled in
the HS group (32 males; 25 females), with an average age of
5.9 ± 4.1 months and a disease course of 3.4 ± 1.7 days.
Fifty-ﬁve participants were in the NS group (31 males; 24
females), with an average age of 5.8 ± 4.3 months and a dis-
ease course of 3.2 ± 1.4 days. No signiﬁcant differences
existed between the two groups (summarized in Table 1).
Outcomes of therapeutic effects
In the HS group, as compared with the NS group, the time
required for wheezing and coughing relief was reduced by
1.2 days on average, the moist crackles vanished 1.8 days
earlier, and the LOS decreased by 1.6 days (Table 2). The
clinical severity scores at baseline were 8.8 ± 1.1 in the HS
group and 8.5 ± 1.5 in the NS group. The clinical severity
scores in the HS group on the ﬁrst, second, third and fourth
days were 5.7 ± 1.5, 3.5 ± 1.1, 2.4 ± 0.9 and 1.7 ± 0.6,
respectively. In the NS group, the clinical severity scores on
the ﬁrst, second, third and fourth days were 7.3 ± 1.7,
1830 Clinical Microbiology and Infection, Volume 17 Number 12, December 2011 CMI
ª2011 The Authors
Journal Compilation ª2011 European Society of Clinical Microbiology and Infectious Diseases, CMI, 17, 1829–1833
5.9 ± 1.5, 4.1 ± 1.1 and 3.1 ± 0.7, respectively. The clinical
severity scores decreased more signiﬁcantly in the HS group
than in the NS group on each day within 96 h after enrol-
ment (Fig. 2).
Adverse events
All participants tolerated therapy without apparent adverse
effects and were eventually discharged after achieving full
recovery. No infants were withdrawn by the medical staff
because of clinical deterioration or the need for intensive-
care support. The coughing and wheezing never worsened
over the course of the treatment. Although ﬁve infants had
hoarse voices, only two of these infants were receiving HS,
and the hoarse voice disappeared after 3–4 days.
Discussion
Bronchiolitis is the most common lower respiratory tract
infection in infants. Wheezing is the primary clinical symp-
tom. The use of inhaled HS to treat viral bronchiolitis was
ﬁrst reported in 2003 [5], and the evidence in favour was
135 patients with moderate to severe ill bronchiolitis were recruited
9 childrens’ parents refused to 
participate in the study
126 patients participated in the study
64 patients in the treatment group 62 patients in the control group
57 patients 
completed 
the whole 
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55 patients 
completed the 
whole study
7 patients 
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after enrolment 
7 patients 
discharged 
within 12 h
after enrolment 
FIG. 1. Flow diagram of the study.
TABLE 1. Comparison of basic clinical information between
the two groups
Basic information
NS group
(n = 55)
HS group
(n = 57) p-Value
Female/male 77.4 78.1 0.98
Age (months) 5.8 ± 4.3 5.9 ± 4.1 0.71
Duration of wheezing
on admission (days)
3.2 ± 1.4 3.4 ± 1.7 0.77
Systemic glucocorticoid
use before admission, no. (%)
35 (77.8) 43 (75.4) 0.82
Clinical score on admission 8.5 ± 1.5 8.8 ± 1.1 0.42
RSV detection rate (%) 40 (72.7%) 42 (73.7%) 0.91
HS, hypertonic saline; NS, normal saline; RSV, respiratory syncytial virus.
TABLE 2. Comparison of symptoms, signs and hospital
length of stay (LOS) between the two groups (x ± s)
Group
Sample
size
Wheezing
relief
(days)
Cough
relief
(days)
Moist
crackles
vanished
(days)
LOS
(days)
HS group 57 3.6 ± 0.9 4.3 ± 0.7 4.4 ± 0.9 4.8 ± 1.2
NS group 55 4.8 ± 1.0 5.5 ± 0.9 6.2 ± 0.7 6.4 ± 1.4
t-Value 4.372 4.915 8.011 4.566
p-Value <0.01 <0.01 <0.01 <0.01
HS, hypertonic saline; NS, normal saline.
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FIG. 2. Clinical severity scores vs. hospitalization days in the two
groups.
CMI Luo et al. Nebulized hypertonic saline treatment in hospitalized children 1831
ª2011 The Authors
Journal Compilation ª2011 European Society of Clinical Microbiology and Infectious Diseases, CMI, 17, 1829–1833
strengthened with the publication of a 2-year extension of
the original study [6]. We previously demonstrated that neb-
ulized HS and salbutamol decreased the clinical symptoms
more quickly and shortened the LOS for infants with mild to
moderate bronchiolitis [7]. The current study demonstrated
that frequently inhaled HS is an effective treatment for
infants with moderate to severe bronchiolitis. It took less
time to relieve symptoms and pulmonary signs: 1.2 days on
average for wheezing and cough alleviation, and 1.8 days for
pulmonary moist crackles to vanish. The clinical severity
scores decreased more signiﬁcantly in the HS group than in
the NS group on each day within 96 h after hospitalization.
The LOS was reduced by 1.6 days, from 6.4 ± 1.4 to
4.8 ± 1.2 days. In our study, patients were discharged when
the patients had experienced no respiratory symptoms and
signs during the past 12 h, whereas in other studies, the dis-
charge criteria were clinical score <4 and SaO2 of at least
95% in room air for 4 h, so the LOS in our study is longer
than in other studies, where the LOS was typically 3–6 days.
A normal height of the periciliary liquid is crucial for nor-
mal airway mucociliary clearance. RSV infection depletes the
mucous layer water content, damages the airway surface
liquid epithelium, and reduces the height of the periciliary
liquid and clearance of mucus [12]. HS may reverse some of
the pathophysiological abnormalities in viral bronchiolitis.
In vitro, HS increases airway surface thickness, decreases epi-
thelial oedema, improves mucus elasticity and viscosity
[13,14], accelerates the transport rates of mucus [14,15],
and improves clearance of mucus [16]. In vivo, HS increases
the rate of mucociliary transport, even in normal subjects
[17]. HS breaks the ionic bonds within the mucous gel and
reduces oedema of the airway wall in viral bronchiolitis
[5,18], causes sputum induction and cough, helps to clear the
sputum, and improves airway obstruction [5]. In this trial,
we did not detect the actual mechanisms. HS improves
mucociliary function and promotes the elimination of mucus,
thereby reducing the adhesion of the virus and consequent
airway inﬂammation reaction, as well as the risk of a second-
ary bacterial infection. However, further investigation is
needed to verify these assumptions.
The pathology of bronchiolitis is peribronchiolar mononu-
clear inﬁltration, epithelial cell necrosis, sub-mucosal oedema
and an increase in the rate of mucous secretion, and there-
fore an increase in the mucin/water ratio [19], which causes
relative a reduction in the airway surface liquid [20]. The
pathophysiology of bronchiolitis is quite distinct from that of
asthma; these patients are less, if at all, responsive to bron-
chodilators [8]. Nebulized HS alone is safe for infants with
moderately severe bronchiolitis [3]. In the current study, we
demonstrated that HS is safe for infants with moderate to
severe bronchiolitis; there were no apparent adverse effects
attributable to frequently inhaled HS. Patients ﬁnished the
entire treatment without bronchospasm, cough or wheezing
aggravation.
In summary, inhaled HS is efﬁcient and safe for infants
with moderate to severe bronchiolitis.
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